Table 1.
Clinical, biological and genetic characteristics of patients stratified according to the CLL-IPI score
| Variable | All patients (n=337) | CLL-IPI score 0–1 Low-risk (n=225) | CLL-IPI score 2–3 Intermediate-risk (n=96) | CLL-IPI score ≥ 4 High-risk (n=16) | P- value |
|---|---|---|---|---|---|
| Age > 65 yrs | 86 (25.5%) | 49 (21.7%) | 28 (29.1%) | 9 (56%) | 0.005 |
| Gender (M/F) | 193/144 | 122/103 | 60/36 | 7/9 | 0.16 |
| Rai stage (≥ I) | 75 (22.2%) | 36 (16%) | 29 (30.2%) | 10 (62.5%) | <0.0001 |
| ALC (109/L) | 11.2 (1.2–131.0) | 10.9 (1.2–131.0) | 11.4 (3.0–64.5) | 15.4 (8.7–101.4) | 0.17 |
| LDH (>UNL) | 17 (5%) | 7 (3.1%) | 8 (8.3%) | 2 (12.5%) | 0.02 |
| B2-M > 3.5 mg/L | 7 (2%) | 2 (0.9%) | 1 (1%) | 4 (25%) | <0.0001 |
| FISH negative | 111 (32.9%) | 71 (31.5%) | 40 (41.6%) | 4 (25%) | |
| 13q del | 153 (45.4%) | 123 (54.6%) | 22 (23%) | 8 (55%) | |
| trisomy 12 | 34 (10%) | 13 (5.7%) | 21 (21.8%) | 0 | |
| 11q del | 14 (4.5%) | 1 (0.4%) | 13 (13.5%) | 0 | |
| TP53 status [normal vs. del(17p) and/or TP53 mutation] | 9 (2.6%) | 0 | 0 | 9 (56%) | <0.0001 |
| IGHV unmutated | 95 (28.1%) | 0 | 79 (82%) | 16 (100%) | <0.0001 |
| CD38-expression (<30%/≥30%) | 274/63 | 206/19 | 55/41 | 7/9 | <0.0001 |
| ZAP-70 expression <20%/≥20%) | 60/261 | 51/166 | 9/86 | 0/9 | 0.005 |